The level of antioxidants, such as thiol-containing tripeptide glutathione (GSH), in cytomegalovirus (CMV)-infected cells is notably increased. We previously showed that GSH levels in plasma, as measured by untargeted 1 H nuclear magnetic resonance, are higher in allogeneic stem cell transplant (allo-SCT) recipients who subsequently develop CMV viraemia. We hypothesized that the net level of oxidative-stress markers present in plasma may be reduced in patients who develop CMV DNAaemia compared to those who do not. We serially monitored the levels of malondialdehyde (MDA) and carbonylated proteins (CPs) early after allo-SCT and assessed whether they could predict the occurrence of CMV DNAaemia. MDA levels were measured in 43 patients (28 had CMV DNAaemia) and CPs were quantified in 53 patients (38 patients developed CMV DNAaemia). The area under the curve (AUC) value for MDA, but not for CPs, was significantly lower in patients who subsequently developed CMV DNAaemia compared to those who remained DNAaemia-free (P=0.043). A trend toward lower MDA AUC values was observed in episodes of CMV DNAaemia with faster CMV replicative kinetics and in those who reached higher peak CMV DNA levels. Moreover, receiver operating characteristic curve analyses indicated that the MDA biomarker had the predictive ability to discriminate between patients with or without subsequent CMV DNAaemia (AUC=0.69, 95 % confidence interval 0.51-0.85, P=0.05). In summary, serial quantitation of MDA may be useful for individualizing antiviral prophylaxis therapies (targeted prophylaxis) in the upcoming era of new antiviral drugs with improved safety profiles.
INTRODUCTION
Cytomegalovirus (CMV) establishes a latent infection in human hosts and can be either reactivated stochastically [1, 2] or triggered by a variety of stimuli, including catecholamine-related stress signals and downstream inflammatory signals such as TNF-a [3, 4] . Cytomegalovirus reactivation frequently occurs in CMV-seropositive allogeneic stem cell transplant (allo-SCT) recipients and can result in significant morbidity, particularly in patients with poorly reconstituted T-cell immunity [5] . While preemptive antiviral therapy is the preferred strategy for preventing CMV endorgan disease there is renewed interest in universal prophylaxis due to the advent of new antivirals with high anti-CMV activity and better safety profiles than those of classic drugs such as ganciclovir and foscarnet [6, 7] .
However, inherent to the choice of universal prophylaxis is the use of anti-CMV drugs in up to 65 % of patients who would never develop CMV disease, even in the absence of preventive measures.
An alternative approach to universal prophylaxis is the restriction of antiviral drug exposure only to patients at the highest risk of CMV viraemia (targeted prophylaxis). However, the precise identification of these patients remains an unmet need. In a recently published proof-of-concept study we found that plasma metabolomic profiling using 1 H nuclear magnetic resonance spectroscopy may prove useful in this respect. Specifically, we built a PLS-DA (projection to latent-structures for discriminant analysis) model which can predict the occurrence of CMV DNAaemia in 73 % of cases [8] . Notably, taurine and the thiol-containing tripeptide glutathione (GSH), both known to mediate antioxidant effects [9] , were upregulated and significantly contributed to this model.
In light of this finding, we hypothesized that the net level of oxidative-stress markers in plasma may be reduced in patients who subsequently develop CMV DNAaemia compared to those who do not. To test this hypothesis we serially monitored the levels of malondialdehyde (MDA) and carbonylated proteins (CPs), markers which are extensively used to identify either reactive oxygen species (ROS)-mediated lipid or protein oxidation, respectively [10] , in plasma samples early after allo-SCT. We then assessed the usefulness of these markers for predicting the subsequent occurrence of CMV DNAaemia in these subjects.
RESULTS

Incidence and features of CMV DNAaemia episodes
Of the 55 patients included in the cohort, 39 developed CMV DNAaemia (first episode) at a median of 34 days (range, 10-84 days) after transplant. Of these, 20 (52.6 %) were preemptively treated with antivirals. The initial and peak CMV DNA loads in these episodes ranged between 20 and 2590 IU ml À1 , and from 83.2 to 420 000 IU ml À1 , respectively, and the episodes lasted between 4 and 149 days. In this cohort, the source of stem cells, donor type, conditioning regimen, donor and recipient CMV paired serostatus, or the graft versus host disease (GvHD) prophylactic regimen used were not significantly associated with Plasma levels of oxidative-stress markers for the prediction of CMV DNAaemia We measured MDA and CP levels in serial plasma specimens (median of three specimens per patient) in all of the patients. The MDA levels could only be measured in 43 patients (because of insufficient plasma sample volume), of whom 28 had CMV DNAaemia. In turn, CPs were quantified in 53 patients, of whom 38 developed CMV DNAaemia. We compared the area under the curve (AUC) and peak values of both markers in patients who did or did not subsequently develop CMV DNAaemia. Representative AUC profiles from patients in both groups are shown in Fig. 1 .
The MDA AUC values (Fig. 2a) were significantly lower in patients who developed CMV DNAaemia than in those who did not (P=0.043). Likewise, we also observed a trend towards lower CP AUC values (Fig. 2b) in patients developing DNAaemia later (P=0.079). The MDA (Fig. 2c ), but not CP (Fig. 2d) , peak levels also tended to be lower in patients who later developed CMV DNAaemia (P=0.075 for MDA and P=0.203 for CPs). The receiver operating characteristic (ROC) curves built on the AUCs for MDA and CPs indicated that only the MDA biomarker (Fig. 3) had sufficient predictive ability to discriminate between patients who did or did not subsequently develop CMV DNAaemia [AUC=0.69, 95 % confidence interval (CI): 0.51-0.85; P=0.05]. However, this discriminatory power was rather modest: a threshold set at the upper 95 % CI value for patients who developed CMV DNAaemia (AUC 5.1) yielded negative and positive predictive values of 78.9 and 45.8 %, respectively.
Interestingly, the AUCs of both markers were lower in episodes of CMV DNAaemia with faster CMV replicative kinetics [CMV DNA doubling time (dt) <2 days) and in those reaching higher peak CMV DNA levels (!1500 IU ml À1 ) which thus required antiviral therapy according to our locally (Table 2) , although the differences did not reach statistical significance.
Baseline transplant parameters and oxidativestress markers present in plasma Two pre-transplant parameters were associated with significantly lower AUCs ( Table 2) or peak MDA levels ( Table 3) : receipt of a haploidentical (and overall HLA-mismatched) allograft and the use of cyclosporin A and mycophenolate mofetil in regimens containing cyclophosphamide for GvHD prophylaxis. No significant associations were found between these transplant parameters and the AUCs or peak levels of CPs (Tables 2 and 3) .
DISCUSSION
In a previous study we showed that the levels of antioxidant taurine and GSH present in plasma early after allo-SCT were elevated in patients who subsequently developed CMV DNAaemia [8] . Based on this finding, we hypothesized that the net level of oxidative-stress markers in plasma may also be simultaneously decreased, and that their quantitation could be useful for predicting the occurrence of CMV DNAaemia. To test this idea in our patient cohort, we serially measured the plasma levels of MDA, an organic compound that results from lipid peroxidation of polyunsaturated fatty acids [11] , and CPs, carbonyl derivatives formed by direct metal-catalysed oxidative attack of the amino acid side chains of proline, arginine, lysine and threonine [12] . The clinical utility of measuring MDA and CPs in order to infer the magnitude of ROSmediated lipid and protein oxidation, respectively, has been previously shown [10] .
The data obtained seemed to support our hypothesis. Specifically, we observed that the MDA AUCs and peak MDA levels were lower in patients who later developed CMV DNAaemia when compared to those measured in study participants with no subsequently documented CMV DNAaemia. In fact, ROC curves built on AUC data for MDA indicated that this biomarker could discriminate, although rather modestly, between patients who did or did not later develop CMV DNAaemia. However, this was not the case for CP AUC or peak CP values. Furthermore, large-series studies have shown that receipt of haploidentical allografts (in conjunction with cyclophosphamide GvHD prophylaxis) or other HLA-mismatched allograft modalities increase the risk of CMV DNAaemia (reviewed in [6, 7, 13] ). In this context, we found that lower MDA AUCs and peak MDA levels were also associated with these graft types.
It is of relevance to highlight that both study groups (patients with or without CMV DNAaemia) were well balanced in terms of age, sex, chemotherapy conditioning and immunosuppressive regimens used for the prevention of acute GvHD, as all these parameters have been shown to modulate the level of oxidative-stress markers in tissues and blood [14] [15] [16] [17] [18] .
It is well known that inflammation triggers CMV reactivation [3] [4] [5] and that oxidative stress and inflammation are closely related pathophysiological processes [19] ; thus, in AUC, area under the curve; CMV, cytomegalovirus; D, donor; HLA, human leukocyte antigen; MDA, malondialdehyde; R, recipient.
*Differences between means were compared using the t-test (to compare two groups) and the ANOVA test (to compare more than two groups).
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this context, our observations may seem counterintuitive. Nevertheless, they can be explained if we assume that CMV reactivates primarily in tissue and organ sites prior to accessing the blood compartment. This has been previously demonstrated in the mCMV murine model [20] and has also been shown to occur in certain clinical settings, such as in intensive care unit patients [21] . In our working pathogenetic model (depicted in Fig. 4 ), CMV reactivation is triggered in tissues in a local and systemic environment of inflammation and oxidative stress likely promoted by highdose chemotherapy used in conditioning and immunosuppressive agents employed for the prevention of acute GvHD [16, 18] . In this sense, both TNF-a [3] and high ROS levels activate NF-kB, which in turn triggers transactivation of the viral immediate-early promoter [3, 4, 22] , a critical step in the completion of the CMV lytic cycle. CMV replication causes cellular stress, leading to the generation of ROS as the by-products of different cellular processes [23] . In response to CMV-induced lytic injury, cells overproduce certain antioxidant enzymes and molecules that remove ROS. Specifically, the level of GSH is notably higher in CMV-infected cells [24, 25] than in their non-infected counterparts. Thus, we speculate that hyperproduction of antioxidants during active CMV replication in tissues may result in a net decrease in oxidative-stress markers, such as MDA and CPs, both locally and later on in the vascular compartment, and that the magnitude of this reduction likely directly correlates with that of CMV replication. Indeed, our data seem to support this idea; we measured lower MDA AUCs and MDA peak levels in active CMV infection episodes with apparently faster virus replication rates (dt <2 days) consequently leading to higher plasma CMV DNA levels.
The main limitations of this present study are its relatively limited sample size and its retrospective nature. It can also be argued that MDA and CP levels do not provide a complete picture of ongoing oxidative-stress processes; AUC, area under the curve; CMV, cytomegalovirus; D, donor; HLA, human leukocyte antigen; MDA, malondialdehyde; R, recipient.
nevertheless, both have been extensively used for that purpose [26] and can directly measure the chemical impact of ROS in biological systems [10] .
In summary, we show for the first time to our knowledge that the measurement of oxidative-stress markers in plasma may help to predict the occurrence of CMV DNAaemia in allo-SCT recipients. In addition to providing further insight into the pathogenesis of CMV reactivation in allo-SCT patients, our findings are also potentially of clinical interest, in that serial quantitation of these biomarkers, MDA in particular, may be useful for individualizing antiviral prophylaxis therapies (targeted prophylaxis) in the upcoming era of new antiviral drugs with improved safety profiles. Nonetheless, validation of our data will require further prospective and statistically robust studies both in allo-SCT recipients and inexperimental settings, such as in the mCMV murine model.
METHODS Patients
This retrospective observational study included 55 non-consecutive patients who underwent allo-SCT for haematological diseases at the Hospital Clínico Universitario in Valencia Diagram of sequential events postulated to lead to a decrease in oxidative-stress markers in plasma prior to the detection of CMV DNAaemia in allo-SCT recipients. High-dose chemotherapy used in conditioning and certain immunosuppressive agents employed for the prophylaxis of acute graft versus host disease (aGvHD) generate a pro-inflammatory and oxidative-stress environment that triggers CMV reactivation in tissues through the action of certain mediators capable of transactivating the CMV immediate-early 1 (IE-1) promoter, such as TNF-a or ROS. CMV replication causes cellular oxidative stress, leading to the overproduction of antioxidant molecules such as thiol-containing tripeptide GSH that remove ROS. MDA and CPs, markers of ROS-mediated lipid or protein oxidation, respectively, increase in tissues and plasma shortly following allo-SCT and further increase in patients in whom CMV reactivates at tissue and organ sites. Local hyperproduction of antioxidants such as GSH ensues as a cellular compensatory mechanisms in an effort to detoxify ROS and avoid further tissue damage. As a result, a net decrease in oxidative-stress markers, such as MDA and CPs, both locally and later on in the vascular compartment, can be evidenced prior to the time of CMV DNAaemia detection. CyA, cyclosporin A; MMF, mycophenolate mofetil; Tacro, tacrolimus.
between 2013 and 2015. The only criterion for patient exclusion was the lack of available consecutive specimens for the experiments described herein. The mean patient age was 50.9 years (range, 18-70 years). The study period comprised the first 100 days after allo-SCT and all the patients gave their written informed consent prior to participating in the study, which was approved by the local Review Board and Ethics Committee (Ethical Commitee of Clinical Research of the Universitary Clínical Hospital of Valencia).
CMV DNAaemia surveillance
Detection of CMV DNAaemia and plasma CMV DNA load monitoring in patients with an active CMV infection was performed using the new RealTime CMV PCR assay from Abbott Molecular, which has a detection limit of approximately 20 copies ml À1 (31 IU ml
À1
; [27] ). The criteria for triggering the initiation of preemptive antiviral therapy or prompting its discontinuation are published elsewhere [28] . Patients treated with preemptive antiviral therapy were administered oral valganciclovir [900 mg (12 ] was used as a second-line therapy. Plasma CMV DNA load monitoring was conducted at least once a week during the study period [28] .
CMV DNA dt calculation
The dt of CMV was estimated based on the first two positive PCR results in the absence of antiviral treatment. The dt was calculated as dt = (t2Àt1)Â log(2)/log(q2/q1), where q1 and t1 are the CMV DNA load (copies ml
À1
) at the time of the first positive PCR result (in days), respectively, and q2 and t2 are the CMV DNA load at the time of the second positive PCR, respectively [29, 30] .
Measurement of oxidative-stress markers A total of 157 cryopreserved plasma specimens were retrieved for the analysis described herein. A median of three specimens (range, 2-3) were available from each patient. These specimens had been obtained at three consecutive time points: at a median of day +8 (range, 1-29), day +17 (range, 5-40) and day +28 (range, 16-61) after allo-SCT. Lipid hydroperoxide MDA was measured via a highperformance liquid chromatography-ultraviolet light (HPLC-UV) assay, as previously described [26] . Briefly, plasma samples (50 µl) were mixed with 0.44 M phosphoric acid and 42 mM thiobarbituric acid (TBA; Sigma-Aldrich, USA) and incubated in a water bath at 95 C for 1 h to hydrolyse the lipoperoxides, liberating malondialdehyde. The samples were immediately cooled and diluted 1 : 1 with alkaline methanol; a process which allows MDA-TBA2 adduct formation. The samples were then centrifuged (13 000 g, for 5 min at 4 C) and 200 µl of the supernatant was mixed 1 : 1 with 50 mM KH 2 PO 4 at pH 3.5. The supernatant was separated by HPLC on RP C18 columns using an isocratic method: phase A consisted of 50 mM KH 2 PO 4 at pH 6.8 and acetonitrile (ACN; KH 2 PO 4 : ACN, 83 : 17); and phase B consisted of a ACN : water (70 : 30) mixture.
The MDA-TBA2 adduct was detected by UV-visible light at 532 nm. To measure oxidized proteins in the plasma, the specimens were derivatized into 2,4-dinitrophenylhydrazone (DNP-hydrazone) by allowing them to react with 2,4-dinitrophenylhydrazine (DNPH), according to the procedure outlined by [31] . Briefly, the protein content in plasma samples were quantified using the Lowry method; 10 µg of proteins from each sample was denatured with 5 µl of 12 % SDS. Then, 10 µl of 10 mM DNPH in 10 % (v/v) trifluoroacetic acid were added to the protein solution. The reaction mixture was neutralized and 10 µl samples were spotted onto a nitrocellulose membrane. The membrane was then blocked with 5 % BSA in Peripheral blood stem cell transplantation (PBST) for 1 h, and incubated with an anti-DNP antibody, as described by the manufacturer (OxyBlot Protein Oxidation Detection kit; Millipore). Images were captured using an ImageQuant LAS-4000 (GE Healthcare Life Sciences) and the signal density was analysed with ImageJ software (NIH Image); each oxidative-stress parameter was measured in triplicate.
Statistical analyses
The frequencies of categorical variables were compared using the 2 -test (Fisher exact test). AUCs were built on GraphPad Prism 6, version 6.01. The AUCs and peak MDA and CP values were then ln-transformed (Napierian logarithm) to make the data conform to normality (ln AUC MDA, P=0.180; ln AUC CPs, P=0.200; ln peak MDA, P=0.200; ln peak CPs, P=0.200 according to the Kolmogorov-Smirnov test). Differences between the means were compared using a t-test (comparing two groups) and an ANOVA test (comparing more than two groups). ROC curves were built and the data were analysed using the statistical package SPSS, version 20.0 (IBM SPSS Statistics). Two-sided exact P-values are reported and P-values <0.05 were considered to be statistically significant.
